Integra LifeSciences Holdings

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Integra LifeSciences posts solid Q4 results, eyes growth opportunities

Integra LifeSciences delivered strong financial performance in Q4 2022 and full-year 2022, showcasing operational resilience and efficiency amidst supply chain challenges and inflationary pressures.
The company's strategic focus on innovation, international growth, and operational excellence positions it well for sustainable growth in 2023, supported by new product launches and market expansion initiatives.
While facing challenges from supply chain disruptions and inflation, Integra's proactive approach to margin expansion, revenue growth, and strategic investments underscores its commitment to long-term value creation.
With a clear roadmap for 2023, including revenue growth targets, margin improvement strategies, and market expansion plans, Integra is poised to navigate challenges and capitalize on opportunities for continued success.

Integra LifeSciences exceeds Q1 expectations, eyes growth amid challenges

Integra LifeSciences demonstrated resilience and growth potential in Q1 2023, with strong segment performances and strategic initiatives.
While facing challenges like supply constraints and margin pressures, the company remains focused on operational efficiency and growth opportunities.
Reaffirmation of guidance, executive appointments, and proactive strategies position Integra well for future growth and market expansion.
Investors can expect improved performance in the second half, driven by new products, supply chain recovery, and strategic investments.

Integra LifeSciences reports Q2 challenges but shows resilience and growth

Integra LifeSciences navigated challenges from a product recall in Q2, showing resilience with solid profitability and growth in unaffected segments.
The company's strategic focus on returning critical technologies to the market, along with new leadership and financial initiatives, positions it for future success.
Despite challenges, Integra LifeSciences remains confident in regaining market share, sustaining growth momentum, and capitalizing on strategic opportunities.
Operational strengths, market performance, and proactive measures to address challenges underscore the company's resilience and growth potential.

Integra LifeSciences navigates Boston impact, eyes growth opportunities post-remediation

Integra LifeSciences faced challenges from the Boston facility recall but showed resilience with strong performance in key segments. The company is focused on growth opportunities post-Boston remediation and maintains a solid financial position. Analysts are optimistic about the company's ability to recover and grow post-recall.

Integra LifeSciences navigates challenges, eyes global growth opportunities

Integra LifeSciences faced challenges from the Boston recall impacting financials but showcased strengths in strategic product relaunches and divisional growth.
The company's performance metrics for 2023 were mixed, with declines in margins but strong cash flow generation. Opportunities lie in global growth catalysts like CereLink.
Looking ahead, Integra aims for revenue recovery post-Q1 headwinds, emphasizing international expansion and product recovery post-recall.

Integra LifeSciences reports strong Q1 results amidst operational challenges

Integra LifeSciences delivered solid Q1 results driven by revenue growth and successful acquisitions.
While facing challenges with the Boston plant audit and supply constraints, the company is focused on key priorities and opportunities for growth.
Maintaining financial stability with a clear plan to address leverage and uncertainties around product reintroduction.
Investors are closely monitoring the company's progress on key initiatives and leadership transition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has completed its previously announced divestiture of its Extremity Orthopedics business to Smith+Nephew (LSE:SN, NYSE:SNN).

Integra LifeSciences Completes the Sale of its Extremity Orthopedics Business to Smith+Nephew

Integra (IART) expects to close the ACell acquisition in the first quarter of 2021, subject to fulfilment of closing conditions.

Integra (IART) to Buy ACell, Expand Regenerative Capability

PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Peter Arduini, president and chief executive officer will present virtually at the 39th Annual J.P. Morgan Healthcare conference on January 14, 2021 at 8:20am ET.

Integra LifeSciences to Present at 39th Annual J.P. Morgan Healthcare Conference

Integra LifeSciences is in the late stages of a transition period, rounded off by the recent divestiture of the orthopaedics segment, to be closed next year. The company has had a strong sequential quarter, which may carry through to Q4 should the pandemic begin to settle over a resurgence.

Integra LifeSciences: Valuation Disconnect, Sell-Side Missing Impact Of Operating Efficiencies

Let's see if Integra LifeSciences (IART) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Pick Integra LifeSciences (IART) Now?

Integra (IART) reported earnings 30 days ago. What's next for the stock?

Integra (IART) Up 24% Since Last Earnings Report: Can It Continue?

Integra's (IART) third-quarter 2020 results reflect mixed segmental performance with strong recovery trends due to coronavirus-led business disruptions.

Integra (IART) Q3 Earnings Surpass Estimates, Margins Up

Integra LifeSciences Holdings Corporation (IART) CEO Peter Arduini on Q3 2020 Results - Earnings Call Transcript

Integra (IART) delivered earnings and revenue surprises of 40.35% and 0.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Tops Q3 Earnings and Revenue Estimates

Shares of Integra Lifesciences (NASDAQ:IART) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 17.65% year over year to $0.80, which beat the estimate of $0.53.

Integra Lifesciences: Q3 Earnings Insights

PRINCETON, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2020.

Integra LifeSciences Reports Third Quarter 2020 Financial Results

ABIOMED

IART vs. ABMD: Which Stock Is the Better Value Option?

Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.

Integra (IART) Preliminary Q3 Results Show Recovery in Sales

PRINCETON, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary third quarter financial results. The company also announced that it will release full third quarter 2020 financial results on Wednesday, October 28, 2020 at 8:30 a.m. ET.

Integra LifeSciences Announces Preliminary Third Quarter Revenue Results; Will Host Third Quarter 2020 Financial Results Conference Call on October 28, 2020

Smith & Nephew

Smith & Nephew 
        SNN, 
        +2.16% 
      
        SN, 
        -0.91% 
       said it's buying the extremity orthopedics unit of Integra LifeSciences 
        IART, 
        -0.40% 
       for $240 million in cash. Smith & Nephew said the deal will provide entry into the shoulder replacement and foot and ankle segment.

Smith & Nephew buying Integra LifeSciences unit

PRINCETON, N.J., Sept.  29, 2020  (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has entered into a definitive agreement to sell its Extremity Orthopedics business to Smith+Nephew (LSE:SN, NYSE:SNN) for $240 million in cash. The transaction is expected to close at or around the end of 2020, subject to the satisfaction of customary conditions including regulatory approvals and consultation with employee representative bodies.

Integra LifeSciences Announces Definitive Agreement to Divest its Extremity Orthopedics Business to Smith+Nephew for $240 Million

Why Is Integra (IART) Down 11.6% Since Last Earnings Report?

PRINCETON, N.J., Sept.  02, 2020  (GLOBE NEWSWIRE) --  Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, announced today that it will participate in two investor conferences in September.

Integra LifeSciences Announces September 2020 Investor Conference Schedule

Integra's (IART) second-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Integra (IART) Q2 Earnings Surpass Estimates, Margins Fall

Integra LifeSciences Holdings (IART) Q2 2020 Results - Earnings Call Transcript

PRINCETON, N.J., Aug.  10, 2020  (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2020.

Integra LifeSciences Reports Second Quarter 2020 Financial Results

On Monday, August 10, Integra Lifesciences (NASDAQ: IART) will release its latest earnings report.

Integra Lifesciences Earnings Preview

Integra LifeSciences (IART) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Integra LifeSciences (IART)

Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra LifeSciences (IART) Expected to Beat Earnings Estimates: Should You Buy?

First and Only Ultrasonic Tissue Ablation System Cleared to Treat Malignant and Benign Tumors, but Not Limited to Meningiomas and Gliomas First and Only Ultrasonic Tissue Ablation System Cleared to Treat Malignant and Benign Tumors, but Not Limited to Meningiomas and Gliomas

News for Integra LifeSciences Holdings Stock (IART)